Role of heart-reactive antibodies in heart failure

Acute Heart Failure Immunomonitoring Cohort Study (AHF-ImmunoCS)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN18181364

Enrollment

381

Registered

2025-02-07

Start date

2022-02-01

Completion date

Unknown

Last updated

2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute heart failure Circulatory System

Interventions

Patients hospitalized for acute heart failure will be followed for 18 months. From blood drawn at baseline, 6 weeks and 6 months after decompensation, the researchers will assess the incidence of hear

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Hospitalization for AHF (consecutive patients, Dept. of Internal Medicine I) 2. Age =18 years 3. Written informed consent 4. Willingness to attend planned follow-up visits at the Comprehensive Heart Failure Center (CHFC) 5. Life expectancy =6 months

Exclusion criteria

Exclusion criteria: 1. High urgency listing for heart transplant 2. High output failure 3. Left ventricular assist device (LVAD) implanted/planned

Design outcomes

Primary

Measure	Time frame
Death or hospitalization for heart failure (HF) in the 18 months following the hospitalization for acute heart failure (AHF), taken from medical records	—

Secondary

Measure	Time frame
1. Cytokine profile, inflammation markers (CRP, IL-6 and other cytokines) in the acute intrahospital phase and at 6 weeks (F6w), 6 months (F6), 12 months (F12) and 18 months (F18) after hospitalization for AHF 2. Adaptive immune response pattern (heart-reactive antibodies) at F6w, F6, F12 and F18: cellular immunophenotypes, anti-myocardial antibody titres and quality, frequencies and differentiation of heart-reactive T cells 3. Cardiac structure and function (echocardiography: LV volume, LVEF, e´) at F6w, F6, F12, and F18 4. Heart failure severity (NYHA, NT-proBNP, 6-min walking distance) at F6w, F6, F12, and F18 5. Hospitalization (for worsening HF and all-cause, respectively) at F6, F12 and F18, taken from medical records 6. Death (cardiac and all-cause, respectively) at F6, F12 and F18, taken from medical records	—

Measure

Time frame

1. Cytokine profile, inflammation markers (CRP, IL-6 and other cytokines) in the acute intrahospital phase and at 6 weeks (F6w), 6 months (F6), 12 months (F12) and 18 months (F18) after hospitalization for AHF 2. Adaptive immune response pattern (heart-reactive antibodies) at F6w, F6, F12 and F18: cellular immunophenotypes, anti-myocardial antibody titres and quality, frequencies and differentiation of heart-reactive T cells 3. Cardiac structure and function (echocardiography: LV volume, LVEF, e´) at F6w, F6, F12, and F18 4. Heart failure severity (NYHA, NT-proBNP, 6-min walking distance) at F6w, F6, F12, and F18 5. Hospitalization (for worsening HF and all-cause, respectively) at F6, F12 and F18, taken from medical records 6. Death (cardiac and all-cause, respectively) at F6, F12 and F18, taken from medical records

—

Countries

Germany

Contacts

Public ContactCaroline Morbach

Morbach_C@ukw.de+49 (0)15757923778

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026